Cipla Ltd News

These are most overbought, oversold stocks on BSE, NSE ahead of Budget 2026

A technical scan on Nifty 500 stocks reveals that 6 shares were trading in overbought territory based on the RSI parameter, while 66 languished in the oversold zone a day ahead of the Union Budget.

ITC, Cipla, Syngene, Dixon, IEX among 69 BSE 500 at 52-week lows on Tuesday

Bata India, Indian Hotels, IGL, MGL, Just Dial, Kalyan Jewellers, Jubilant FoodWorks, Oberoi Realty, Mankind Pharma and Suzlon Energy have hit their respective 52-week lows.

Cipla shares decline post Q3; brokerages slash targets on US headwinds

In Q3, Cipla's net profit dropped 57 per cent year-on-year (Y-o-Y) to ₹675 crore, as compared to ₹1,570.51 crore a year ago

Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA

Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug Administration. As per its latest Enforcement Report, the US-based arm of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication to treat dandruff and skin conditions with inflammation and itching. The Princeton (New Jersey)-based Sun Pharmaceutical Industries Inc is recalling 24,624 bottles of Fluocinolone Acetonide Solution Topical Solution for "Failed Impurities/Degradation Specifications", the US health regulator said. The company initiated the Class III nationwide (US) recall on December 30, 2025. The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris. Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results f

Cipla Q3 results: Net profit slumps 57% to ₹675 crore on US supply issues

Bets on respiratory product launches and peptides for growth

Cipla Q3FY26 results: Profit falls 57% to ₹676 crore, revenue flat

Cipla Q3 Results: The decline in Cipla's profit was primarily due to a production halt at the exclusive manufacturer of Lanreotide, the company's second-largest revenue-contributing tumour drug

Q3 results today: BPCL, Cipla, JSW Steel among 54 firms on Jan 23

Q3FY26 company results: Firms including IndusInd Bank, Adani Green Energy, Godrej Consumer Products, India Cements, and JSW Energy are also to release their October-December earnings reports today

FDA observation to hit Lanreotide supply; Cipla may face earnings risk

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations

Cipla slips 5%, hits nine-month low; why pharma stock under pressure?

In the past seven trading days, the stock price of Cipla has slipped 11 per cent from ₹1,530.25 hit on January 1, 2026.

Stocks to Watch today, Jan 8: Cipla, Tata Steel, Meesho, Shriram Fin, MCX

Stocks to Watch today, January 8, 2026: From Tata Steel to Cipla, here is a list of stocks that will be on investors' radar

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Cipla rolls out Afrezza inhaled insulin in India after CDSCO approval

Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an awareness drive on insulin adherence

Cipla to exclusively market and distribute five Pfizer brands in India

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Pfizer, Cipla sign exclusive marketing, distribution deal for 4 brands

Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and

Stocks to watch, Dec 11: Tata Steel, SBI, Bank of Baroda, Cipla, KEI Ind

Stocks to watch on December 11: Puravankara, Petronet LNG and Prestige Estates are among other top stocks to track today

Cipla, Stempeutics launch stem cell therapy for knee osteoarthritis

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA

Cipla launches India's first integrated lung diagnostics, wellness centre

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care

Stocks to Watch today, Nov 4: Bharti Airtel, Titan, Hero MotoCorp, Cipla

Stocks to Watch today, November 4, 2025: From Bharti Airtel, Hero MotoCorp, Titan Company, and Power Grid, here is a list of stocks that will be in focus today

Cipla Q2 revenue grows, margins squeeze; analysts decode stock strategy

In the Q2FY26, Cipla reported consolidated revenue from operations of ₹7,589 crore, up 8 per cent year-on-year (Y-o-Y) from ₹7,051 crore in the year-ago period